Opko Health, Inc. (OPK): EBITDA
-$25.78M
Year ended 2025-12-31
$41.47M
Trailing 12 months to 2026-06-30
| Period ended | EBITDA | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | -$25.78M | n/m | 2026-02-26, From 2025-01-01 |
| 2024-12-31 | -$53.89M | n/m | 2026-02-26, From 2024-01-01 |
| 2023-12-31 | -$51.72M | n/m | 2026-02-26, From 2023-01-01 |
| 2022-12-31 | -$117.60M | n/m | 2025-03-03, From 2022-01-01 |
| 2021-12-31 | $97.47M | -31.9% | 2024-03-01, From 2021-01-01 |
| 2020-12-31 | $143.08M | n/m | 2023-02-27, From 2020-01-01 |
| 2019-12-31 | -$180.25M | n/m | 2022-03-01, From 2019-01-01 |
| 2018-12-31 | -$73.85M | n/m | 2021-02-18, From 2018-01-01 |
| 2017-12-31 | -$174.35M | n/m | 2020-03-02, From 2017-01-01 |
| 2016-12-31 | $25.0K | n/c | 2019-03-01, From 2016-01-01 |
| 2015-12-31 | -$56.23M | n/m | 2018-03-01, From 2015-01-01 |
| 2014-12-31 | -$130.89M | n/m | 2017-03-01, From 2014-01-01 |
| 2013-12-31 | -$64.42M | n/m | 2016-02-29, From 2013-01-01 |
| 2012-12-31 | -$27.11M | n/m | 2015-02-27, From 2012-01-01 |
| 2011-12-31 | -$19.36M | n/m | 2014-03-03, From 2011-01-01 |
| 2010-12-31 | -$8.93M | n/m | 2013-03-18, From 2010-01-01 |
| 2009-12-31 | -$21.58M | n/a | 2012-03-15, From 2009-01-01 |
EBITDA at similar companies
| Company | Year ended | EBITDA | Change YoY |
|---|---|---|---|
| Opko Health, Inc. (OPK) | 2025-12-31 | -$25.78M | n/m |
| TG Therapeutics, Inc. (TGTX) | 2025-12-31 | $123.38M | +193.8% |
| Organogenesis Holdings Inc. (ORGO) | 2025-12-31 | $59.97M | +386.0% |
| HUTCHMED (China) Ltd (HCM) | 2025-12-31 | -$25.85M | n/m |
| Ultragenyx Pharmaceutical Inc. (RARE) | 2025-12-31 | -$500.00M | n/m |
| Kiniksa Pharmaceuticals International, plc (KNSA) | 2025-12-31 | $78.78M | n/m |
| Mirum Pharmaceuticals, Inc. (MIRM) | 2025-12-31 | $2.11M | n/m |
| Supernus Pharmaceuticals, Inc. (SUPN) | 2025-12-31 | $29.28M | -81.9% |
| Pacira BioSciences, Inc. (PCRX) | 2025-12-31 | $110.21M | n/m |
Compare OPK, TGTX, ORGO, HCM side by side · Screen every company in Pharmaceutical Preparations ↗